Drug Search Results
More Filters [+]

CB-020

Alternative Names: CB-020, CB020, CB 020
Latest Update: 2022-12-12
Latest Update Note: Clinical Trial Update

Product Description

CB-020 is a iNK cell candidate for the treatment of solid tumors. (Sourced from: https://www.cariboubio.com/pipeline/)

Mechanisms of Action: CAR-T

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Caribou Biosciences
Company Location: BERKELEY CA 94710
Company CEO: Rachel E. Haurwitz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CB-020

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events